New antibiofilm strategies for the management of nontuberculous mycobacteria diseases.

IF 2.5 3区 医学 Q3 PHARMACOLOGY & PHARMACY
Expert Opinion on Pharmacotherapy Pub Date : 2024-10-01 Epub Date: 2024-10-09 DOI:10.1080/14656566.2024.2412250
María Cano-Fernández, Jaime Esteban
{"title":"New antibiofilm strategies for the management of nontuberculous mycobacteria diseases.","authors":"María Cano-Fernández, Jaime Esteban","doi":"10.1080/14656566.2024.2412250","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Nontuberculous mycobacteria (NTM) represent a group of microorganisms comprising more than 190 species. NTM infections have increased recently, and their treatment is a major challenge because to their resistance to conventional treatments. This review focuses on innovative strategies aimed at eradicating NTM biofilms, a critical factor in their resistance. Important areas addressed include biofilm formation mechanisms, current therapeutic challenges, and novel treatment approaches. The main objective is to compile and analyze information on these emerging strategies, identifying pivotal research directions and recent advancements.</p><p><strong>Areas covered: </strong>A review of the scientific literature was conducted to identify emerging novel therapies for the treatment of NTM infections and to explore potential synergies with existing treatments.</p><p><strong>Expert opinion: </strong>Experts highlights a limited understanding of optimal treatment regimens, often supported by insufficient scientific evidence. Current therapies are typically prolonged, involve multiple antibiotics with adverse effects, and frequently do not achieve patient cure. Certain species are even considered virtually impossible to eradicate. A thorough understanding of these new approaches is imperative for improving patients outcomes. This review provides a robust foundation for developing of more effective antibacterial strategies, which are essential because of the increasing incidence of NTM infections and the limitations of existing therapies.</p>","PeriodicalId":12184,"journal":{"name":"Expert Opinion on Pharmacotherapy","volume":" ","pages":"2035-2046"},"PeriodicalIF":2.5000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Opinion on Pharmacotherapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14656566.2024.2412250","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/10/9 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Nontuberculous mycobacteria (NTM) represent a group of microorganisms comprising more than 190 species. NTM infections have increased recently, and their treatment is a major challenge because to their resistance to conventional treatments. This review focuses on innovative strategies aimed at eradicating NTM biofilms, a critical factor in their resistance. Important areas addressed include biofilm formation mechanisms, current therapeutic challenges, and novel treatment approaches. The main objective is to compile and analyze information on these emerging strategies, identifying pivotal research directions and recent advancements.

Areas covered: A review of the scientific literature was conducted to identify emerging novel therapies for the treatment of NTM infections and to explore potential synergies with existing treatments.

Expert opinion: Experts highlights a limited understanding of optimal treatment regimens, often supported by insufficient scientific evidence. Current therapies are typically prolonged, involve multiple antibiotics with adverse effects, and frequently do not achieve patient cure. Certain species are even considered virtually impossible to eradicate. A thorough understanding of these new approaches is imperative for improving patients outcomes. This review provides a robust foundation for developing of more effective antibacterial strategies, which are essential because of the increasing incidence of NTM infections and the limitations of existing therapies.

治疗非结核分枝杆菌疾病的抗生物膜新策略。
导言:非结核分枝杆菌(NTM)是由 190 多种微生物组成的微生物群。近来,非结核分枝杆菌感染呈上升趋势,由于它们对传统治疗方法具有抗药性,因此治疗非结核分枝杆菌是一项重大挑战。本综述重点关注旨在根除 NTM 生物膜的创新策略,生物膜是 NTM 耐药性的关键因素。涉及的重要领域包括生物膜的形成机制、当前的治疗挑战以及新型治疗方法。主要目的是汇编和分析有关这些新兴策略的信息,确定关键的研究方向和最新进展:对科学文献进行了综述,以确定治疗 NTM 感染的新兴新型疗法,并探讨与现有疗法的潜在协同作用:专家强调,人们对最佳治疗方案的了解有限,而且往往缺乏足够的科学证据支持。目前的疗法通常持续时间较长,涉及多种抗生素并有不良反应,而且常常无法治愈患者。某些种类甚至被认为几乎不可能根除。要改善患者的治疗效果,就必须对这些新方法有透彻的了解。本综述为制定更有效的抗菌策略奠定了坚实的基础,由于 NTM 感染的发病率越来越高,而现有疗法又存在局限性,因此制定更有效的抗菌策略至关重要。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
5.60
自引率
3.10%
发文量
163
审稿时长
4-8 weeks
期刊介绍: Expert Opinion on Pharmacotherapy is a MEDLINE-indexed, peer-reviewed, international journal publishing review articles and original papers on newly approved/near to launch compounds mainly of chemical/synthetic origin, providing expert opinion on the likely impact of these new agents on existing pharmacotherapy of specific diseases.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信